Line Kibsgaard

Line Kibsgaard

Auto-generated profile, based on publicly available information

Line Kibsgaard

Department of Dermatology and Venereology Aarhus University Hospital Aarhus Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in International Journal of Women's Dermatology
Verified
Journal Article
Open access
LKLine Kibsgaard
Line Kibsgaard
MDMette Deleuran
Mette Deleuran
CFCarsten Flohr
Carsten Flohr
SLSinéad Langan
Sinéad Langan
AOAnne Braae Olesen
Anne Braae Olesen
CVChristian Vestergaard
Christian Vestergaard
There are limited estimates of the incidence rates (IRs) of mastocytosis, and only a few studies have addressed the long-term consequences of living with these diagnoses. Previous reports have shown that systemic mastocytosis is associated with leukemic transformations and an increased risk of death as opposed to cutaneous mastocytosis (CM) and indolent systemic mastocytosis (ISM), which have benign diagnoses with life expectancy rates similar to those of the background population. This study aimed to analyze the incidence and mortality of mastocytosis. A population-based matched cohort study of patients with mastocytosis between 1 January 1, 1977 and 31 December 31, 2014 was identified from the Danish National Health Registries. IRs of CM, ISM, and pediatric mastocytosis were highlighted. Survival estimates were compared with those of a healthy background population, using a Cox proportional hazard model. A total of 1461 patients with mastocytosis were identified. The annual IR of overall mastocytosis was 1.1 per 100,000 person years (95% confidence interval [CI], 1.0–1.2). Among children, the IR was 1.8 per 100,000 person years (95% CI, 1.6–2.1). The prevalence of any comorbidity was twice as high among patients with mastocytosis compared with the population without mastocytosis (odds ratio: 2.1; 95% CI, 1.8–2.5). The Charlson Comorbidity Index–adjusted mortality among adult patients with mastocytosis was HRCutaneous Mastocytosis 1.2 (95% CI, 0.8–1.9), HRIndolent Systemic Mastocytosis 1.9 (95% CI 1.4–2.5), and HRSystemic Mastocytosis 4.2 (95%, CI 1.9–9.4), respectively. Based on an entire nation, with free health care at the point of access, we estimated an annual IR of mastocytosis and its subgroups. We discovered that patients with ISM had an increased risk of death compared with the general population. Our data supported the overall benign nature of CM diagnosed after age 2 years.

MNMie Fryd Nielsen
Mie Fryd Nielsen
JAJane Agergaard
Jane Agergaard
RMRebecca Vigh Margolinsky
Rebecca Vigh Margolinsky
LKLine Kibsgaard
Line Kibsgaard
MHMette Holm
Mette Holm
Christian WejseChristian Wejse
Christian Wejse
(1) Background: Post-arrival screening for infectious diseases is routinely offered to newly arrived refugees in Denmark, including tests for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and syphilis. This study aimed to examine the cascade of care following positive screening results in a local cohort of refugees in Denmark, with a focus on subsequent clinical management, follow-up, and outcomes. (2) Methods: This retrospective cohort study included 1506 newly arrived refugees of all ages and countries of origin. All were offered a post-arrival infectious disease screening in Denmark. Clinical records were reviewed to assess progression through the cascade of care, including referral, evaluation, follow-up, and clinical outcomes among individuals with positive screening results. (3) Results: Of the 1506 screened refugees, 33 (2.2%) had at least one positive screening result. Among the 15 individuals with detectable hepatitis B surface antigen, six (43%) attended regular follow-up, while eight (57%) were lost during the cascade of care. Two participants screened positive for HCV antibodies; both underwent initial clinical evaluation, but their subsequent care trajectories differed due to repeated non-attendance or undocumented reasons. Only one participant with non-specific syphilis antibodies completed follow-up in accordance with national guidelines. One participant was diagnosed with HIV and successfully linked to care. (4) Conclusions: The prevalence of screened infectious diseases in this local Danish refugee cohort was low and consistent with findings from comparable settings. Although post-arrival screening facilitates the identification of infectious diseases, substantial loss to follow-up occurred after initial diagnosis, limiting the effectiveness of follow-up and treatment. These findings highlight the need for targeted, interdisciplinary strategies addressing organisational, social, and individual barriers to improve continuity of care following screening.

18 October 2026 in BJU International
Verified
Journal Article
Open access
JMJanni Mølsted
Janni Mølsted
AAAnne Birgitte Als
Anne Birgitte Als
Jørgen Bjerggaard JensenJørgen Bjerggaard Jensen
Jørgen Bjerggaard Jensen
MAMikael Aagaard
Mikael Aagaard
LLLisa Anni Larsen Lethan
Lisa Anni Larsen Lethan
JJJakob Kristian Jakobsen
Jakob Kristian Jakobsen
Objectives: To present and describe the design, data collection framework, and interim cohort characteristics of the PENIMA project, a multicentre initiative establishing a clinically annotated penile lesion image repository to support future artificial intelligence (AI)‐driven decision‐support development – and to encourage urology and dermatology colleagues working with penile lesions to participate in the project. Patients and Methods: Prospective participant inclusion commenced in March 2023 across Scandinavian urological and dermatological departments. Patients with penile anatomy undergoing clinically indicated genital examination are invited to participate and provide oral and written consent as defined by local authority regulations. Clinical photographs and structured metadata are collected. Lesion classification is based on a specialist evaluation, clinical follow‐up and histopathology when available. Images are pseudonymised and annotated using a secure, containerised Computer Vision Annotation Tool (CVAT) environment. Supervised machine‐learning model development using convolutional neural networks is planned with patient‐level dataset partitioning and evaluation using standard diagnostic performance metrics. The study was approved by relevant local authorities, and the approval number is 1‐10‐72‐150‐22. Results: As of February 2026, 1125 participants and approximately 7000 images have been included. In all, 40% represented normal anatomical variants. Among lesional cases, 33% are clinically assessed as benign, 13% premalignant, and 8% malignant; 22% of all cases have histopathological verification. Concordance between clinical suspicion and histopathology is highest for penile carcinoma (84.6%, 95% confidence interval 75.0–91.0%). Conclusion: The PENIMA project includes a multicentre, clinically grounded image repository reflecting real‐world penile lesion presentations. The feasible and successful infrastructure provides a foundation for future development and validation of image‐based clinical decision‐support tools.